Clinical trials · Washington, D.C., DC
Prostate cancer clinical trials in Washington, D.C.
We’re tracking 118 recruiting prostate cancer studies with a site in or near Washington, D.C. — including Early Phase 1, Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Washington, D.C.
- NCT05176483RecruitingPhase 1
New drug combinations for advanced solid tumors
This trial tests a new drug called zanzalintinib, which may slow or shrink various types of advanced cancer. It is given together with other cancer treatments, and the study is looking at many different cancers including kidney, prostate, bladder, lung, liver, and more.
Baltimore, MarylandAges 18 years+ - NCT07209176Recruiting
Why men may not get genetic testing for prostate cancer
This study looks at why some men with metastatic prostate cancer do or don't get a genetic test called NGS. It aims to find barriers to testing, so doctors can better help patients in the future.
Baltimore, MarylandAges 18 years+ - NCT06389097Recruiting
SPECT Scans to Improve Treatment for Advanced Cancer
This study uses special scans (SPECT imaging) to see how radium or lutetium treatments move through your body, helping doctors plan better doses. It's for people with advanced prostate cancer (getting Radium-223) or advanced neuroendocrine tumors (getting 177Lu treatments).
Baltimore, MarylandAges 18–100 - NCT04104776RecruitingPhase 1/Phase 2
Test drug tulmimetostat for advanced cancers and lymphomas
This early-phase study tests tulmimetostat (DZR123) to shrink or control advanced solid tumors and certain lymphomas, and it may also test a combination in some prostate cancer groups. If you qualify, you’ll receive the study drug and be monitored closely, including blood tests and a request for tumor tissue to look for biomarkers.
Baltimore, MarylandAges 18 years+ - NCT04503265RecruitingPhase 1/Phase 2
AMXI-5001 study for advanced cancers that won’t respond
This Phase 1/2 trial tests AMXI-5001 in people with advanced cancers that have progressed or stopped responding to standard treatments. It’s mainly designed to find the safest dose and see early signs the treatment might work.
Baltimore, MarylandAges 18 years+ - NCT05125016RecruitingPhase 1/Phase 2
Study drug for advanced prostate cancer after standard treatments
This early-phase study tests whether REGN4336 is safe and how well it works, by itself or with REGN5678, in adults with advanced prostate cancer. It may help people whose cancer has continued to worsen despite standard prostate cancer medicines.
Baltimore, MarylandAges 18 years+ - NCT05939414RecruitingPhase 3
Study of radioactive drug for prostate cancer that has spread a little
This study tests a radioactive drug (177Lu-PSMA-617) compared to no immediate treatment in men with prostate cancer that has returned and spread to a few spots (oligometastatic). It aims to see if this treatment delays the spread of cancer and improves outcomes.
Baltimore, MarylandAges 18–100 - NCT06826924Recruiting
Fasting or ketones for prostate cancer
This trial tests whether a 7-day water-only fast or taking ketone supplements can help treat prostate cancer. You would have a biopsy before and after to see how the tumor responds.
Baltimore, MarylandAges 18 years+ - NCT03151629Recruiting
Registry for men with advanced prostate cancer
This study is a worldwide registry that collects health information from men with advanced prostate cancer. It may help researchers better understand disease patterns and outcomes, which can guide future treatments.
Baltimore, MarylandAges 21 years+ - NCT03861676RecruitingEarly Phase 1
PET-guided targeted radiation for early prostate cancer
This early-phase study tests a precise, targeted radiation treatment for prostate cancer, using a special PET scan to help plan exactly where to treat. It may help reduce the amount of radiation to surrounding tissues while treating the cancer.
Baltimore, MarylandAges 18–100 - NCT05519449RecruitingPhase 1
Testing a PSMA-targeting treatment for advanced prostate cancer
This Phase 1 trial tests JANX007 in men with metastatic castration-resistant prostate cancer (cancer that keeps growing despite standard hormone treatment). It aims to find a safe dose and see whether the treatment can shrink tumors or slow progression.
Baltimore, MarylandAges 18–100 - NCT05691465RecruitingPhase 2
Radiation drug for metastatic prostate cancer with neuroendocrine cells
This Phase 2 study tests whether a radioactive medicine called lutetium Lu 177 dotatate is safe and effective for metastatic prostate cancer that has neuroendocrine features. It also checks whether patients’ scans show the cancer absorbs the drug (a requirement to start treatment).
Baltimore, MarylandAges 18 years+ - NCT06059118RecruitingPhase 2
High-dose testosterone and a drug for advanced prostate cancer
This trial tests a combination of high-dose testosterone with enzalutamide and difluoromethylornithine (DFMO) for men whose prostate cancer has spread and stopped responding to standard hormone therapy. It aims to see if this approach can shrink tumors or slow the cancer's growth.
Baltimore, MarylandAges 18 years+ - NCT06801236RecruitingPhase 1
A new drug for advanced prostate cancer that has stopped responding to treatment
This early-phase trial tests a new study drug called ACE-232 for men with advanced prostate cancer that has stopped responding to standard hormone therapy and chemotherapy. It aims to see if the drug is safe and may help slow the cancer.
Baltimore, MarylandAges 18 years+ - NCT04704505RecruitingPhase 2
Testosterone-like treatment plus radium for bone-spread prostate cancer
This trial studies whether adding a testosterone-related therapy (BAT) to radium-223 can better control prostate cancer that has spread mainly to the bones. It may help shrink tumors in the bone and slow PSA rises, which are a common marker of prostate cancer activity.
Baltimore, MarylandAges 18 years+ - NCT06616597RecruitingPhase 2
Targeting gut bacteria to help prostate cancer treatment work again
This trial tests whether adding metronidazole, an antibiotic, can make abiraterone work better in men with metastatic prostate cancer whose PSA is rising despite treatment. It aims to target gut bacteria that may be fueling resistance to the therapy.
Baltimore, MarylandAges 18 years+ - NCT02871726Recruiting
Robot-assisted ultrasound biopsy of the prostate
This trial tests a robot-assisted method to take prostate tissue samples using an ultrasound probe placed through the rectum. It may help patients and doctors get clearer biopsy results when there are early warning signs of prostate problems, before a cancer diagnosis is confirmed.
Baltimore, MarylandAges 45–75 - NCT06855277RecruitingPhase 3
AAA817 with hormone therapy for advanced prostate cancer
This trial tests a new combination treatment (AAA817 plus a hormone therapy) against standard care for men with advanced PSMA-positive prostate cancer that has spread and stopped responding to a previous hormone therapy. It may be an option if you haven't had certain prior treatments.
Baltimore, MarylandAges 18–100 - NCT06172478RecruitingPhase 2
HER3-DXd for advanced solid tumors after prior treatment
This trial tests a new targeted drug called HER3-DXd for people with several types of advanced solid tumors that have stopped responding to standard treatments. The drug is an antibody-drug conjugate, designed to deliver chemotherapy directly to cancer cells that have a protein called HER3 on their surface.
Baltimore, MarylandAges 18 years+ - NCT07181161RecruitingPhase 1/Phase 2
Testing a new drug for metastatic prostate cancer
This trial tests an investigational drug (AZD0516) alone or with other treatments in men with prostate cancer that has spread to other parts of the body and is no longer responding to hormone therapy. It aims to see if the drug can help control the cancer.
Towson, MarylandAges 18–130 - NCT06134232RecruitingPhase 2
Extra sipuleucel-T after Provenge for prostate cancer
This trial tests whether adding one extra infusion of sipuleucel-T (the same drug as Provenge) after the standard three doses can help men with advanced prostate cancer that no longer responds to hormone therapy. It is for men who have already finished their three Provenge infusions and have mild or no symptoms.
Towson, MarylandAges 18 years+ - NCT07332000RecruitingPhase 2
Gene therapy and radiation for intermediate-risk prostate cancer
This trial tests a new gene therapy (aglatimagene besadenovec) given as an injection into the prostate before standard radiation therapy for men with intermediate-risk prostate cancer. The goal is to see if adding this treatment can improve outcomes.
Towson, MarylandAges 18 years+
Hear when a new Prostate cancer trial opens near Washington, D.C., DC
We’ll email you when one opens near Washington, D.C., DC — at most once a week, no account needed, unsubscribe anytime.
Prostate cancer trials in other cities
Where these studies are running near Washington, D.C.
Institutions with a site for the recruiting prostate cancer studies listed above.
- Johns Hopkins University · 6 studies
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · 4 studies
- Chesapeake Urology Research Associates · 2 studies
- University of Maryland/Greenebaum Cancer Center · 2 studies
- Amber Michalik
- Chesapeake Urology Associates
- Exelixis Clinical Site #14
- Johns Hopkins Kimmel Com Cancer Ctr
What taking part in a prostate cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting prostate cancer studies in District of Columbia.
Common questions
- Are there prostate cancer clinical trials near Washington, D.C.?
- Yes. We're currently tracking 118 recruiting prostate cancer studies with a site near Washington, D.C., each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a prostate cancer study near Washington, D.C.?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Washington, D.C. to take part?
- Not necessarily. These studies have a site near Washington, D.C., but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a prostate cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New prostate cancer studies open near Washington, D.C. regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.